Cdk9 Activators
Cyclin-dependent kinase 9 (Cdk9) is a pivotal member of the cyclin-dependent kinase family, playing a central role in the regulation of cell cycle progression and transcriptional processes. Cdk9 is a component of the positive transcription elongation factor b (P-TEFb) complex, which is crucial for RNA polymerase II phosphorylation and efficient transcriptional elongation. This kinase is intricately involved in controlling the expression of genes related to cell proliferation, apoptosis, and cellular responses to DNA damage. Cdk9 activators constitute a diverse group of chemical compounds that exert modulatory effects on Cdk9 activity, thereby influencing critical cellular processes. Flavopiridol, a potent Cdk inhibitor, indirectly activates Cdk9 by disrupting the cell cycle through the inhibition of other Cdks, such as Cdk2 and Cdk4. DRB, a transcriptional inhibitor, is another Cdk9 activator that influences Cdk9 activity by affecting RNA polymerase II phosphorylation. The impact of DRB on transcriptional regulation leads to Cdk9 recruitment and activation, emphasizing the intricate interplay between transcriptional processes and Cdk9 activation. R-roscovitine, a cyclin-dependent kinase inhibitor, further contributes to Cdk9 activation by disrupting both the cell cycle and transcriptional processes.
JQ1, a bromodomain inhibitor, introduces another layer of complexity to Cdk9 activation by indirectly influencing Cdk9 through targeting bromodomain-containing proteins such as BRD4. SNS-032, a selective Cdk inhibitor, acts as an additional Cdk9 activator by disrupting both the cell cycle and transcriptional processes. The resulting compensatory mechanisms enhance Cdk9 activation, illustrating the adaptability of cellular systems in response to perturbations in Cdk activity. Within the chemical class of Cdk9 activators, compounds like AZD4573, Alsterpaullone, and DRF-1042 selectively inhibit Cdk9, exerting influence over transcriptional processes and positively modulating Cdk9 activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB is a transcriptional inhibitor that indirectly activates Cdk9 by influencing RNA polymerase II (RNAPII) phosphorylation. By inhibiting transcription elongation, DRB leads to the accumulation of hyperphosphorylated RNAPII, which in turn recruits Cdk9 to phosphorylate the C-terminal domain of RNAPII. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
R-roscovitine is a cyclin-dependent kinase inhibitor that indirectly activates Cdk9 by affecting the cell cycle and transcriptional processes. Its inhibition of Cdks, including Cdk2 and Cdk7, can lead to compensatory mechanisms that enhance Cdk9 activation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a bromodomain inhibitor that indirectly activates Cdk9 by targeting bromodomain-containing proteins, such as BRD4. Inhibition of BRD4 disrupts the formation of the positive transcription elongation factor b (P-TEFb) complex, releasing Cdk9 to phosphorylate RNAPII and activate transcription. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor of Cdks, including Cdk9. Its indirect activation of Cdk9 is mediated by disrupting the cell cycle and transcriptional processes. Inhibition of other Cdks, such as Cdk2 and Cdk7, can lead to compensatory mechanisms that enhance Cdk9 activation. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a multi-CDK inhibitor that indirectly activates Cdk9 by targeting multiple Cdks, including Cdk1, Cdk2, and Cdk5. The inhibition of these Cdks disrupts the cell cycle and triggers compensatory mechanisms that enhance Cdk9 activation. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a pan-CDK inhibitor that indirectly activates Cdk9 by disrupting the cell cycle and transcriptional processes. Its inhibition of multiple Cdks, including Cdk2 and Cdk4, can lead to compensatory mechanisms that enhance Cdk9 activation. | ||||||
RGB-286638 | 784210-88-4 | sc-507523 | 250 mg | $285.00 | ||
RGB-286638 is a selective Cdk9 inhibitor that can indirectly activate Cdk9 by influencing transcriptional processes. Its selective inhibition of Cdk9 disrupts the positive transcription elongation factor b (P-TEFb) complex, releasing Cdk9 to phosphorylate RNAPII and activate transcription. | ||||||
Voreloxin | 175414-77-4 | sc-475094 | 2.5 mg | $380.00 | ||
SNS-595, also known as Voreloxin, is a topoisomerase II inhibitor that indirectly activates Cdk9 by influencing transcriptional processes. Its inhibition of topoisomerase II can lead to DNA damage and trigger compensatory mechanisms that enhance Cdk9 activation. | ||||||